<DOC>
	<DOC>NCT00920543</DOC>
	<brief_summary>The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma</brief_summary>
	<brief_title>GSK BHR Study (Sont)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Asthma diagnosis Controller medications or moderate inhaled corticosteroid dose Evidence of reversibility Lifethreatening asthma Asthma instability Concurrent respiratory disease Drug allergy Respiratory tract infection Systemic corticosteroid use Immunosuppressive medication use Positive pregnancy test Tobacco use Site affiliation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>